CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
- PMID: 25878332
- DOI: 10.1158/1078-0432.CCR-14-3190
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Abstract
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
©2015 American Association for Cancer Research.
Comment on
-
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398450
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
